PHARMGEN SCIENCE INC

What PHARMGEN SCIENCE INC does

PharmGen Science Inc. is a South Korean pharmaceutical and biotechnology company publicly listed on the KOSPI stock exchange under ticker 004720, headquartered at the Bangbae Campus in Seoul and operating additional R&D, manufacturing, and office campuses in Hwaseong-si (Hyangnam Campus for pharmaceutical R&D and manufacturing, Dongtan Campus for general operations). The company's stated core technology focus is on next-generation MRI contrast agents for diagnostic imaging and preclinical research supporting new drug development; the company positions its differentiation as domain specialization in non-clinical candidate-substance evaluation. Its sole disclosed commercial target segment is healthcare and medical imaging, with the value proposition centered on improving the diagnostic completeness of candidate substances through non-clinical evaluation and on strengthening R&D cooperation in preclinical research.

The company's business model is anchored on pharmaceutical R&D and manufacturing operations rather than on disclosed product sales or pricing. No public pricing, customer logos, revenue, ARR, or distribution channels are disclosed in the input, reflecting either pre-commercial status on its lead program or limited public disclosure consistent with a small-cap Korean listed entity. The company has no disclosed subsidiaries, parent company, or controlling entity, and operates under standard Korean public-company corporate governance led by CEO Park Hee-deok (Park Hee-deok / 박희덕). Internal disclosure control regulations were formalized in 2009 with subsequent updates in 2020, aligning the firm with the statutory disclosure regime applicable to KOSPI issuers.

The most recent material strategic action is a June 2026 MOU with K-MEDI hub (Daegu-Gyeongbuk Advanced Medical Industry Promotion Foundation) to establish mutual R&D cooperation in preclinical research and new drug development, including a specific workstream for non-clinical evaluation of PharmGen Science's next-generation MRI contrast agent candidate. This partnership signals an ecosystem-buildout approach to advancing the imaging-agent pipeline through shared infrastructure, researcher exchanges, and joint research rather than through disclosed acquisitions, large capital raises, or in-licensing deals.

Name

PHARMGEN SCIENCE INC

Legal name

PharmGen Science, Inc.

Website

https://pharmgenscience.com

Company type

Public

Founded year

2009

Operating status

Operating

Short description

PharmGen Science Inc. is a KOSPI-listed South Korean pharmaceutical and biotech company developing next-generation MRI contrast agents and conducting preclinical drug research, operating R&D and manufacturing campuses in Seoul and Hwaseong-si under CEO Park Hee-deok.

Ownership category

akta.pro rank

Product category

Pharmaceutical R&D and Diagnostic Imaging Agents

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAIALAF

Translational Medicine & Biomarkers

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

SECONDARYHLAIAAAB

Specialty Care Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• MRI contrast agents
• Pharmaceutical manufacturing
• Preclinical research services
• New drug development
• Diagnostic imaging agents

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Infrastructure, Personnel, Operations

Core offering

PharmGen Science develops and manufactures pharmaceutical products, primarily next-generation MRI contrast agents for medical imaging diagnostics. The company also conducts preclinical research and new drug development, leveraging shared research infrastructure with partner organizations such as K-MEDI hub.

Product overview

PharmGen Science Inc. is a Korean pharmaceutical/biotechnology company listed on KOSPI (stock: 004720). The company focuses on new drug development and preclinical research, including next-generation MRI contrast agents. The company operates multiple campuses in South Korea and has established R&D partnerships with medical industry organizations.

Differentiator

Problem solved

Functional benefit

Products and services

• Next-Generation MRI Contrast Agent
• Preclinical Research Services
• New Drug Development

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• K-MEDI hub (Daegu-Gyeongbuk Advanced Medical Industry Promotion Foundation)coreStrategic or Co-development Partner · 25 June 2026PharmGen Science signed an MOU with K-MEDI hub to establish mutual cooperation in preclinical research and new drug development. The agreement aims to strengthen R&D cooperation by linking new drug development capabilities and preclinical research infrastructure, including joint research systems, researcher exchanges, and shared utilization of advanced research facilities. K-MEDI hub preclinical center specifically plans to conduct research cooperation for non-clinical evaluation of PharmGen Science's next-generation MRI contrast agent to enhance the development completeness of candidate substances.

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Direct peers

• GE HealthCare: GE HealthCare is a global leader in MRI contrast media (e.g., Clariscan, Gadavist competitor products) and a major imaging-equipment OEM. Directly comparable to PharmGen Science as a developer and supplier of MRI contrast agents serving radiology departments.
• Guerbet: Guerbet is a specialty contrast-media and imaging-solutions company focused on MRI (Dotarem) and interventional radiology. Highly comparable to PharmGen Science as a contrast-agent pure-play with diagnostic-imaging orientation.
• Lantheus Holdings: Lantheus is a radiopharmaceutical/diagnostic-imaging specialist with a focus on agents used in MRI and nuclear medicine. Comparable to PharmGen Science on a contrast/diagnostic-imaging R&D-and-commercialization model.
• Bracco Imaging: Bracco is one of the world's largest dedicated contrast-media companies (ProHance, MultiHance, gadolinium-based MRI agents). Closely comparable to PharmGen Science on R&D specialization in next-generation MRI contrast agents.

Regional players

• Samsung Biologics: Samsung Biologics is a Korean-listed biopharmaceutical contract manufacturer with large-scale mammalian and microbial facilities. Comparable to PharmGen Science as a KOSPI-listed Korean pharma with operational manufacturing infrastructure and Asian geographic exposure.
• Celltrion: Celltrion is a Korean biosimilars and novel biologics developer/manufacturer with global ambitions. Comparable to PharmGen Science on the KOSPI-KRX listed pharma profile and on the integration of R&D, manufacturing, and regulatory execution in South Korea.
• Yuhan Corporation: Yuhan is one of Korea's largest established pharmaceutical companies with branded and specialty therapeutics plus manufacturing footprint. Comparable to PharmGen Science as a Korean pharma operator with manufacturing campuses serving domestic and export channels.

Emerging players

• Telix Pharmaceuticals: Telix develops diagnostic and therapeutic radiopharmaceuticals across oncology and imaging, including novel MRI-adjacent agents. Comparable as a smaller, R&D-driven diagnostic-imaging pharma player pursuing next-generation imaging agents.
• Curium: Curium focuses on nuclear medicine and diagnostic radiopharmaceuticals, overlapping with PharmGen Science on next-generation diagnostic-agent development and global imaging-customer channels.

Broad incumbents

• Bayer Pharmaceuticals: Bayer markets Gadavist, a leading gadolinium-based MRI contrast agent, within a broader diversified pharmaceutical and imaging portfolio. Comparable to PharmGen Science on the MRI contrast vector while operating as a much larger incumbent across many therapeutic areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PHARMGEN SCIENCE INC